chr2-47471062-G-T
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM1PM2PM5PP3_StrongPP5_Moderate
The NM_000251.3(MSH2):c.1759G>T(p.Gly587Cys) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G587R) has been classified as Pathogenic.
Frequency
Consequence
NM_000251.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MSH2 | NM_000251.3 | c.1759G>T | p.Gly587Cys | missense_variant, splice_region_variant | 11/16 | ENST00000233146.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MSH2 | ENST00000233146.7 | c.1759G>T | p.Gly587Cys | missense_variant, splice_region_variant | 11/16 | 1 | NM_000251.3 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 20
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 22, 2024 | The c.1759G>T pathogenic mutation (also known as p.G587C), located in coding exon 11 of the MSH2 gene, results from a G to T substitution at nucleotide position 1759. The amino acid change results in glycine to cysteine at codon 587, an amino acid with highly dissimilar properties. However, this change occurs in the last base pair of coding exon 11, which makes it likely to have some effect on normal mRNA splicing. This variant has been identified in a proband(s) whose Lynch syndrome-associated tumor demonstrated loss of MSH2 expression by immunohistochemistry (Ambry internal data).This mutation was reported in a proband with HNPCC, and RNA analysis confirmed it resulted in aberrant splicing yielding p.Ser554Argfs*11 (Sjursen W et al. Mol Genet Genomic Med, 2016 Mar;4:223-31). In addition, an ex vivo minigene splicing assay on genomic DNA revealed exon 11 skipping as a result of another alteration at this position (c.1759G>C; p.G587R), which as been detected in one suspected Lynch syndrome family and has been classified as pathogenic by multifactorial analysis (Bonadona V et al. JAMA, 2011 Jun;305:2304-10; Tournier I et al. Hum. Mutat. 2008 Dec;29:1412-24; Thompson BA et al. Nat. Genet. 2014 Feb;46:107-115). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at